- Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia, and South Africa.
- Microdox is a super-oxidized solution based on Sonoma's patented Microcyn Technology intended to treat and prevent infections in the urinary tract and bladder.
- Microdox is a non-irritating and non-toxic solution and is ready for immediate use. It is currently available through Sonoma's partners, Te Arai BioFarma in New Zealand and Australia, and NuAngle in South Africa.
- Also See: Sonoma Pharma Expands Its Partner Network For Oral, Dental Products In US & China.
- "We believe Microdox is a unique bladder irrigation that fulfills the requirements of an effective adjunct UTI prevention and treatment for removing UTI-causing bacteria, bacterial biofilms, and drug-resistant strains," said Scott Lissington, COO of Te Arai BioFarma.
- Price Action: SNOA shares are up 8.33% at $3.64 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Sonoma Pharma Launches New Urinary Tract Infection Product In New Zealand, Australia, South Africa
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks